Erik Ames

1.2k total citations
26 papers, 965 citations indexed

About

Erik Ames is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Erik Ames has authored 26 papers receiving a total of 965 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Immunology, 13 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Erik Ames's work include Immune Cell Function and Interaction (18 papers), T-cell and B-cell Immunology (11 papers) and CAR-T cell therapy research (6 papers). Erik Ames is often cited by papers focused on Immune Cell Function and Interaction (18 papers), T-cell and B-cell Immunology (11 papers) and CAR-T cell therapy research (6 papers). Erik Ames collaborates with scholars based in United States, Australia and United Kingdom. Erik Ames's co-authors include William J. Murphy, Mingyi Chen, Steven K. Grossenbacher, William Hallett, Robert J. Canter, Arta M. Monjazeb, Thomas J. Sayers, Isabel Barão, Rachel Smith and Gail D. Sckisel and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Blood and Immunity.

In The Last Decade

Erik Ames

24 papers receiving 951 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Erik Ames United States 15 740 488 178 160 51 26 965
Anushruti Sarvaria United Kingdom 4 566 0.8× 448 0.9× 149 0.8× 116 0.7× 30 0.6× 4 755
Christine M. Ho United States 6 645 0.9× 541 1.1× 227 1.3× 59 0.4× 28 0.5× 13 865
Weiqing Jing United States 15 479 0.6× 452 0.9× 225 1.3× 248 1.6× 17 0.3× 29 825
Erika Falisi Italy 9 1.2k 1.6× 560 1.1× 217 1.2× 65 0.4× 40 0.8× 10 1.3k
Jérôme Mastio United States 10 631 0.9× 346 0.7× 319 1.8× 84 0.5× 48 0.9× 11 908
Jiaxiong Tan China 16 447 0.6× 443 0.9× 185 1.0× 158 1.0× 24 0.5× 37 742
Cyril Šálek Czechia 14 311 0.4× 275 0.6× 243 1.4× 201 1.3× 39 0.8× 47 728
Iñigo Terrén Spain 14 594 0.8× 289 0.6× 167 0.9× 62 0.4× 51 1.0× 25 816
Anna Koutoulaki Greece 5 659 0.9× 255 0.5× 182 1.0× 63 0.4× 40 0.8× 9 834
Mehrdad Mohseni United States 5 575 0.8× 184 0.4× 107 0.6× 87 0.5× 33 0.6× 7 728

Countries citing papers authored by Erik Ames

Since Specialization
Citations

This map shows the geographic impact of Erik Ames's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Ames with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Ames more than expected).

Fields of papers citing papers by Erik Ames

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik Ames. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Ames. The network helps show where Erik Ames may publish in the future.

Co-authorship network of co-authors of Erik Ames

This figure shows the co-authorship network connecting the top 25 collaborators of Erik Ames. A scholar is included among the top collaborators of Erik Ames based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik Ames. Erik Ames is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Ames, Erik, María C. Ochoa, Myriam Fernández-Sendin, et al.. (2022). Killers on the loose: Immunotherapeutic strategies to improve NK cell-based therapy for cancer treatment. International review of cell and molecular biology. 370. 65–122. 6 indexed citations
3.
Ames, Erik & Oscar Silva. (2021). Polytypic T-cell prolymphocytic leukemia. Blood. 137(15). 2125–2125.
4.
Luna, Jesus I., Steven K. Grossenbacher, Ian R. Sturgill, et al.. (2019). Bortezomib Augments Natural Killer Cell Targeting of Stem-Like Tumor Cells. Cancers. 11(1). 85–85. 21 indexed citations
5.
Ames, Erik, Michael J. Campbell, Alaa Afify, Jeffrey F. Krane, & Eric C. Huang. (2018). Sclerosing mucoepidermoid carcinoma with eosinophilia: Cytologic characterization of a rare distinct entity in the thyroid. Diagnostic Cytopathology. 46(7). 632–635. 10 indexed citations
6.
Canter, Robert J., Steven K. Grossenbacher, Erik Ames, & William J. Murphy. (2016). Immune targeting of cancer stem cells in gastrointestinal oncology.. PubMed. 7(Suppl 1). S1–S10. 13 indexed citations
7.
Sckisel, Gail D., Myriam N. Bouchlaka, Arta M. Monjazeb, et al.. (2015). Out-of-Sequence Signal 3 Paralyzes Primary CD4+ T-Cell-Dependent Immunity. Immunity. 43(2). 240–250. 88 indexed citations
8.
Ames, Erik, Robert J. Canter, Steven K. Grossenbacher, et al.. (2015). Enhanced targeting of stem-like solid tumor cells with radiation and natural killer cells. OncoImmunology. 4(9). e1036212–e1036212. 63 indexed citations
9.
Ames, Erik, Robert J. Canter, Steven K. Grossenbacher, et al.. (2015). NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype. The Journal of Immunology. 195(8). 4010–4019. 181 indexed citations
10.
Canter, Robert J., Erik Ames, Steven K. Grossenbacher, et al.. (2014). Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma. BMC Cancer. 14(1). 756–756. 20 indexed citations
11.
Ames, Erik, et al.. (2014). Natural Killer Cell Subsets Differentially Reject Embryonic Stem Cells Based on Licensing. Transplantation. 97(10). 992–998. 16 indexed citations
12.
Grossenbacher, Steven K., et al.. (2014). Enhanced natural killer cell targeting of cancer stem cells using Cetuximab. Journal for ImmunoTherapy of Cancer. 2(S3). 5 indexed citations
13.
Pai, Chien-Chun Steven, Mingyi Chen, Annie Mirsoian, et al.. (2014). Treatment of chronic graft-versus-host disease with bortezomib. Blood. 124(10). 1677–1688. 53 indexed citations
14.
Ames, Erik & William J. Murphy. (2013). Advantages and clinical applications of natural killer cells in cancer immunotherapy. Cancer Immunology Immunotherapy. 63(1). 21–28. 78 indexed citations
15.
Tang-Feldman, Yajarayma, Erik Ames, Maite Álvarez, et al.. (2013). Murine natural killer cell licensing and regulation by T regulatory cells in viral responses. Proceedings of the National Academy of Sciences. 110(18). 7401–7406. 34 indexed citations
16.
Barão, Isabel, Maite Álvarez, Erik Ames, et al.. (2011). Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independently of MHC. Blood. 117(26). 7032–7041. 41 indexed citations
17.
Ames, Erik, et al.. (2011). The Triterpenoid CDDO-Me Promotes Hematopoietic Progenitor Expansion and Myelopoiesis in Mice. Biology of Blood and Marrow Transplantation. 18(3). 396–405. 5 indexed citations
18.
Álvarez, Maite, Erik Ames, Isabel Barão, et al.. (2011). Mouse NK cell–mediated rejection of bone marrow allografts exhibits patterns consistent with Ly49 subset licensing. Blood. 119(6). 1590–1598. 34 indexed citations
19.
Ames, Erik, William Hallett, & William J. Murphy. (2009). Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition. Clinical & Experimental Immunology. 155(3). 504–513. 37 indexed citations
20.
Hallett, William, Erik Ames, Maite Álvarez, et al.. (2008). Combination Therapy Using IL-2 and Anti-CD25 Results in Augmented Natural Killer Cell–Mediated Antitumor Responses. Biology of Blood and Marrow Transplantation. 14(10). 1088–1099. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anushruti Sarvaria Breakdown of academic impact, for papers by Christine M. Ho Breakdown of academic impact, for papers by Weiqing Jing Breakdown of academic impact, for papers by Erika Falisi Breakdown of academic impact, for papers by Jérôme Mastio Breakdown of academic impact, for papers by Jiaxiong Tan Breakdown of academic impact, for papers by Cyril Šálek Breakdown of academic impact, for papers by Iñigo Terrén Breakdown of academic impact, for papers by Anna Koutoulaki Breakdown of academic impact, for papers by Mehrdad Mohseni
Rankless by CCL
2026